KAPOSI SARCOMA IN LUNG TRANSPLANT RECIPIENTS: EXPLORING THE CONNECTION WITH MSM DONOR RISK CRITERIA (CHEST 2025) - Jul 1, 2025 - Abstract #Poster 4642; Pres time: Oct 22, 2025; 10:20 AM - 11:05 AM; Location: McCormick Place - Lakeside Center Exhibit Hall Poster Area 5; "All 3 LTRs with KS received basiliximab induction at the time of transplant, 1 was treated with tocilizumab for COVID-19 3 months prior to KS diagnosis, and all 3 were on standard 3-drug immunosuppression (tacrolimus, mycophenolate mofetil (MMF), and prednisone)...All 3 LTRs with KS were on CMV prophylaxis with concurrent herpes virus coverage (2 on valganciclovir and 1 on letermovir and acyclovir)... LTRs with MSM donors are at risk for post-LT KS. Radiographic presentations of KS varied; however, immunohistochemical tissue staining was universally HHV8 positive. Treatment response was favorable; however, the sample size was very small."
Clinical • Epstein-Barr Virus Infections • Infectious Disease • Kaposi Sarcoma • Novel Coronavirus Disease • Oncology • Sarcoma • Solid Tumor • Transplantation
|
|
SHOAIB AHMAD; DEVIKA SINDU; ALI IMR; SAEED ROSS M; BREMNER RAJAT; WALIA MICHAEL; NAILOR CHRISTINE; PHAM; SOFYA TOKMAN
|